23 July 2025 Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.
22 July 2025
22 July 2025
18 July 2025
Latest Features
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.
Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report.
Europe
Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
More News
17 July 2025 Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency.
17 July 2025 Three of the new shareholders have IP and life sciences expertise, bringing a commercial and policy focus to the firm.
16 July 2025 Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents.
16 July 2025 LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines.
15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.
15 July 2025 Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.
14 July 2025 This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of increased transparency requirements in clinical trials and their effects on the global patent system. The session focuses on recent regulatory changes, especially in Europe, and the challenges they present for IP protection.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox